Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom [Seeking Alpha]
Annovis Bio, Inc. (ANVS)
Company Research
Source: Seeking Alpha
14min Summary Annovis Bio's Buntanetap shows promising results in treating Alzheimer's and Parkinson's, with significant cognitive and motor function improvements in Phase 2/3 and Phase 3 trials. The drug also improved motor function in Phase 3 Parkinson's trials, especially in advanced cases and PIGD patients. Buntanetap's mechanism of action targets neurotoxic proteins, offering symptomatic and possibly disease-modifying benefits, making it a valuable IP for combination therapies. Buntanetap showed statistically significant cognitive improvement in Phase 2/3 Alzheimer's trials, particularly at 15mg and 30mg doses. Unfortunately, its short cash runway can't be ignored. So, I maintain a "hold" rating on ANVS until it secures more long-term financing. Daria Kulkova/iStock via Getty Images Annovis Bio, Inc. ( NYSE: ANVS ) develops treatments for neurodegenerative diseases like Alzheimer's, Parkinson's, and Lewy Body Dementia. The company targets alterations in axonal tr
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- Annovis Bio, Inc. (NYSE:ANVS) surges 24%; retail investors who own 56% shares profited along with insiders [Yahoo! Finance]Yahoo! Finance
- Annovis Bio, Inc. (NYSE: ANVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Annovis Bio Reports Second Quarter Financial Results and Provides Business UpdateGlobeNewswire
- Annovis Bio, Inc. (NYSE: ANVS) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.MarketBeat
ANVS
Earnings
- 5/10/24 - Beat
ANVS
Sec Filings
- 8/15/24 - Form 8-K
- 8/14/24 - Form 10-Q
- 8/6/24 - Form 8-K
- ANVS's page on the SEC website